Mark G. Foletta serves as Executive Vice President and Chief Financial Officer of Tocagen Inc. He also currently serves on the Board of Directors of DexCom, Inc., where he is the Lead Director and Chairman of the Audit Committee, AMN Healthcare Services, Inc., where his is the Chairman of the Audit Committee, and Viacyte, Inc., a privately held biotechnology company, where he also is Chairman of the Audit Committee.
Mark previously served as the Interim Chief Financial Officer of Biocept, Inc. from August 2015 to July 2016 and as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc. from March 2006 until October 2012. From March 2000 to March 2006, he served as Vice President, Finance and Chief Financial Officer of Amylin. From 1987 to 1999, Mark held various financial management positions with Intermark, Inc. and Triton Group Ltd. He started his career with Ernst & Young in the San Diego office.
Mark’s previous Board of Director positions include Regulus Therapeutics Inc. from 2013 to 2018, Ambit Biosciences Corporation from 2015 until 2016, and Anadys Pharmaceuticals, Inc. from 2007 to 2011.
In 2016, Mark was awarded the Lifetime Achievement Award at the San Diego Business Journal’s Annual CFO of the Year Awards. Mark received a Bachelor of Arts degree from the University of California, Santa Barbara. He is also a Certified Public Accountant (inactive).